RecruitingNCT06839300

The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study


Sponsor

AO Foundation, AO Spine

Enrollment

260 participants

Start Date

Feb 9, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

To determine the accuracy of serum NF-L and GFAP levels (ie the biomarkers) at different time points postinjury for predicting the severity of neurologic impairment at 6 months postinjury as either motor complete (AIS grade A/B) or motor incomplete (AIS grade C/D) a group of patients who suffer traumatic spinal fracture and/or dislocation of the spinal column but without neurologic injury will be enrolled as non-SCI spine trauma control participants.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with spinal cord injury. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(8)

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Prince of Wales Hospital

Sydney, Randwick NSW, Australia

Cajuru University Hospital

Curitiba, Paraná, Brazil

Clinica Alemana de Santiago

Santiago, Vitacura, Chile

Charité Berlin

Berlin, Germany

Sri Balaji Action Medical Institute

New Delhi, India

MIddlemore Hospital

Auckland, Otahuhu, New Zealand

King's College Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06839300


Related Trials